2022
Mo1160: EXTERNAL VALIDATION OF A PREDICTIVE MODEL DETERMINING RISK OF NEOPLASTIC PROGRESSION OF BARRETT'S ESOPHAGUS IN A COHORT OF UNITED STATES VETERANS
Nguyen T, Thrift A, Ketwaroo G, Du X, Novelo L, George R, Rosen D, El-Serag H. Mo1160: EXTERNAL VALIDATION OF A PREDICTIVE MODEL DETERMINING RISK OF NEOPLASTIC PROGRESSION OF BARRETT'S ESOPHAGUS IN A COHORT OF UNITED STATES VETERANS. Gastroenterology 2022, 162: s-719. DOI: 10.1016/s0016-5085(22)61693-7.Peer-Reviewed Original Research
2021
Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells
Tran TT, Rane CK, Zito CR, Weiss SA, Jessel S, Lucca L, Lu BY, Oria VO, Adeniran A, Chiang VL, Omay SB, Hafler DA, Kluger HM, Jilaveanu LB. Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. Cancers 2021, 13: 1049. PMID: 33801444, PMCID: PMC7958624, DOI: 10.3390/cancers13051049.Peer-Reviewed Original ResearchPDCD4 expressionImproved survivalTumor-associated immune cellsTumor microenvironmentNeoplastic progressionBrain metastasis outcomesExtracranial metastatic diseaseMelanoma brain metastasesNatural killer cellsBrain metastasis samplesImmune cell infiltrationImmune cell subsetsMultiple tissue microarraysExpression of PDCD4Brain metastasesMetastatic diseaseClinical outcomesKiller cellsClinicopathological variablesIntracranial metastasesCell subsetsCell infiltrationCell death 4Immune cellsPrimary melanoma
2019
Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas arising from an intraductal papillary mucinous neoplasm
Charifa A, Walther Z, Salem R, Jain D. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas arising from an intraductal papillary mucinous neoplasm. Human Pathology Reports 2019, 15: 95-98. DOI: 10.1016/j.ehpc.2018.12.007.Peer-Reviewed Case Reports and Technical NotesOsteoclast-like giant cellsUndifferentiated carcinomaInvasive carcinomaGiant cellsMucinous neoplasmsEndoscopic ultrasoundIntraductal papillary mucinous neoplasmIntraductal mucinous neoplasmPapillary mucinous neoplasmRare pancreatic tumorPancreatic ductal carcinomaDuctal lesionsDuctal carcinomaPancreatic tumorsPancreatic adenocarcinomaCarcinoma subtypesHistological examinationPancreatic massCarcinomaEpithelial markersAmpullary massEpithelial originIPMNNeoplastic progressionNeoplasms
2009
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes & Development 2009, 23: 2152-2165. PMID: 19759263, PMCID: PMC2751988, DOI: 10.1101/gad.1820109.Peer-Reviewed Original ResearchConceptsPrimary tumorMouse modelHallmark capabilitiesPancreatic neuroendocrine tumorsAnti-angiogenic therapyTranscription factor ZEB1MiR changesMiR-200 familyMetastatic tumorsNeuroendocrine tumorsRare subsetEnhanced metastasisAngiogenesis inhibitorsMetastasisTumorsMiR signatureNeoplastic progressionHuman tumorsAltered expressionAdaptive resistanceExpression signaturesE-cadherinCancerMiRTherapy
2004
A DNA polymerase β mutant from colon cancer cells induces mutations
Lang T, Maitra M, Starcevic D, Li SX, Sweasy JB. A DNA polymerase β mutant from colon cancer cells induces mutations. Proceedings Of The National Academy Of Sciences Of The United States Of America 2004, 101: 6074-6079. PMID: 15075389, PMCID: PMC395925, DOI: 10.1073/pnas.0308571101.Peer-Reviewed Original ResearchConceptsMisincorporation of nucleotidesK289MM proteinPol beta proteinC base substitutionMouse L cellsMutation frequencyColon cancer cellsSpontaneous mutation frequencyDNA pol betaDNA positioningLys-289Mutational targetMouse cellsAltered positioningBase substitutionsColorectal carcinomaBacterial cellsTarget sequencePol betaProteinTemplate GLambda DNANeoplastic progressionBeta protein
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply